GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Up 85.2% in May

GeoVax Labs Inc. (NASDAQ:GOVX) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 470,940 shares, a growth of 85.2% from the April 30th total of 254,323 shares. Based on an average daily volume of 835,393 shares, the days-to-cover ratio is presently 0.6 days. Approximately 13.6% of the shares of the company are short sold.

Institutional Investors Weigh In On GeoVax Labs

Institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC purchased a new position in shares of GeoVax Labs during the first quarter valued at $27,000. Hudson Bay Capital Management LP purchased a new position in GeoVax Labs in the third quarter valued at about $47,000. HRT Financial LP purchased a new position in GeoVax Labs in the fourth quarter valued at about $31,000. Sabby Management LLC bought a new stake in shares of GeoVax Labs during the 3rd quarter worth about $313,000. Finally, Armistice Capital LLC bought a new stake in shares of GeoVax Labs during the 3rd quarter worth about $253,000. 6.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a research report on Thursday, April 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Reduce” and a consensus target price of $150.00.

GeoVax Labs Stock Performance

GOVX opened at $2.03 on Thursday. GeoVax Labs has a one year low of $0.96 and a one year high of $34.75. The stock’s fifty day moving average is $1.63 and its 200-day moving average is $3.66. The company has a market capitalization of $7.04 million, a PE ratio of -0.11 and a beta of 3.62.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Wednesday, April 15th. The company reported $1.85 EPS for the quarter. On average, equities research analysts forecast that GeoVax Labs will post -8.69 EPS for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.